Skip to main content
Erschienen in: Current Infectious Disease Reports 9/2018

01.09.2018 | Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)

Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools

verfasst von: Zachary A. Rubin, Elise M. Martin, Paul Allyn

Erschienen in: Current Infectious Disease Reports | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Clostridium difficile infection (CDI) is a major cause of morbidity and mortality in hospitalized patients and rates in most places have not decreased significantly despite broad efforts by both hospitals and public health entities. This review aims to provide readers with a better understanding of the limitations of current prevention strategies. We also review potential future tools that may be available for the primary prevention of CDI in the next decade.

Recent Findings

Research over the last decade has expanded our appreciation of the role of asymptomatic shedding in the healthcare setting and in the community. This review demonstrates that poor quality data underlies even well-established guidance from national authorities on basic topics such as contact precautions, avoidance of alcohol-based hand hygiene products, CDI testing, supplemental cleaning modalities, and the use of bleach solutions. Additionally, we review research on novel preventative interventions such as identification of asymptomatic carriers, supplemental environmental cleaning technologies, vaccines, and the manipulation of the intestinal microbiome. While there is preliminary data that supports further research in all of these areas, the research is not yet robust enough on which to base local or national policy recommendations, though late-phase human clinical trials of CDI vaccine trials are ongoing.

Summary

Over the last decade, researchers have begun to reassess the traditional infection prevention model for CDI. Data suggesting a greater role for asymptomatic shedders has increased our understanding of current vertical prevention techniques and is forcing researchers to look more at new processes and technologies to decrease disease incidence.
Literatur
1.
Zurück zum Zitat Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. New Engl J Med. 2015;372:825–34.CrossRefPubMed Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. New Engl J Med. 2015;372:825–34.CrossRefPubMed
2.
Zurück zum Zitat Zilberg MD, Shorr AF, Koleff MH. Increase in adult Clostridium difficile-related hospitalizations and case fatality rate, United States, 2000-2005. Emerg Infect Dis. 2008;14:929–31.CrossRef Zilberg MD, Shorr AF, Koleff MH. Increase in adult Clostridium difficile-related hospitalizations and case fatality rate, United States, 2000-2005. Emerg Infect Dis. 2008;14:929–31.CrossRef
3.
Zurück zum Zitat Reveles KR, Lee GC, Boyd NK, Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010. Am J Infect Dis. 2014;42:1028–32. Reveles KR, Lee GC, Boyd NK, Frei CR. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010. Am J Infect Dis. 2014;42:1028–32.
4.
Zurück zum Zitat See I, Mu Y, Cohen J, Beldavs ZG, Winston LG, Dumyati G, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infectious Dis. 2014;58:1394–400.CrossRef See I, Mu Y, Cohen J, Beldavs ZG, Winston LG, Dumyati G, et al. NAP1 strain type predicts outcomes from Clostridium difficile infection. Clin Infectious Dis. 2014;58:1394–400.CrossRef
5.
Zurück zum Zitat Scardina T, Labuszewski L, Pacheco SM, Adams W, Schreckenberger P, Johnson S. Clostridium difficile infection (CDI) severity and outcome among patients infected with the Nap1/B1/027 strain in non-epidemic setting. Infect Control Hosp Epidemiol. 2015;36:280–6.CrossRefPubMed Scardina T, Labuszewski L, Pacheco SM, Adams W, Schreckenberger P, Johnson S. Clostridium difficile infection (CDI) severity and outcome among patients infected with the Nap1/B1/027 strain in non-epidemic setting. Infect Control Hosp Epidemiol. 2015;36:280–6.CrossRefPubMed
6.
Zurück zum Zitat Bauer KA, Johnston JEW, Wenzler E, Goff DA, Cook CH, Balada-Llasat JM, et al. Impact of the NAP-1 strain on disease severity, mortality and recurrence of healthcare-associated Clostridium difficile infection. Anaerobe. 2017;48:1–6.CrossRefPubMed Bauer KA, Johnston JEW, Wenzler E, Goff DA, Cook CH, Balada-Llasat JM, et al. Impact of the NAP-1 strain on disease severity, mortality and recurrence of healthcare-associated Clostridium difficile infection. Anaerobe. 2017;48:1–6.CrossRefPubMed
8.
Zurück zum Zitat •• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018. This article provides the most up to date guidance from public health. •• McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018. This article provides the most up to date guidance from public health.
9.
Zurück zum Zitat Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:S48–65.CrossRefPubMed Dubberke ER, Carling P, Carrico R, Donskey CJ, Loo VG, McDonald LC, et al. Strategies to prevent Clostridium difficile infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:S48–65.CrossRefPubMed
10.
Zurück zum Zitat Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines: guidelines for Clostridium difficile infection in adults: 2010 update by the Society of Healthcare Epidemiology of America (SHEA) and in the Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 2010;31:431–55. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines: guidelines for Clostridium difficile infection in adults: 2010 update by the Society of Healthcare Epidemiology of America (SHEA) and in the Infectious Diseases Society of America. Infect Control Hosp Epidemiol. 2010;31:431–55.
11.
Zurück zum Zitat McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–10.CrossRefPubMed McFarland LV, Mulligan ME, Kwok RYY, Stamm WE. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–10.CrossRefPubMed
12.
Zurück zum Zitat Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis. 2013;57:1094–102.CrossRefPubMedPubMedCentral Curry SR, Muto CA, Schlackman JL, Pasculle AW, Shutt KA, Marsh JW, et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis. 2013;57:1094–102.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat •• Donskey CJ, Kundrapa S, Despande A. Colonization versus carriage of Clostridium difficile. Infect Dis Clin N Am. 2015;29:13–28. Well researched review of the evidence surrounding asymptomatic carriage of CD. CrossRef •• Donskey CJ, Kundrapa S, Despande A. Colonization versus carriage of Clostridium difficile. Infect Dis Clin N Am. 2015;29:13–28. Well researched review of the evidence surrounding asymptomatic carriage of CD. CrossRef
14.
Zurück zum Zitat Sethi AK, Al-Nassir WN, Nerandzic MM, et al. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidem. 2010;32:21–7.CrossRef Sethi AK, Al-Nassir WN, Nerandzic MM, et al. Persistence of skin contamination and environmental shedding of Clostridium difficile during and after treatment of C. difficile infection. Infect Control Hosp Epidem. 2010;32:21–7.CrossRef
15.
Zurück zum Zitat Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45:992–8.CrossRefPubMed Riggs MM, Sethi AK, Zabarsky TF, Eckstein EC, Jump RLP, Donskey CJ. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45:992–8.CrossRefPubMed
16.
Zurück zum Zitat Jinno S, Kundrapu S, Guerrero DM, Jury LA, Nerandzic MM, Donskey CJ. Potential for transmission of Clostridium difficile by asymptomatic acute care patients and long-term care facility residents with prior C. difficile infection. Infect Contr Hosp Epidemiol. 2012;33:638–9.CrossRef Jinno S, Kundrapu S, Guerrero DM, Jury LA, Nerandzic MM, Donskey CJ. Potential for transmission of Clostridium difficile by asymptomatic acute care patients and long-term care facility residents with prior C. difficile infection. Infect Contr Hosp Epidemiol. 2012;33:638–9.CrossRef
17.
Zurück zum Zitat • Fuyura-Kanamori L, Riley TV, Paterson DL, et al. Comparison of Clostridium difficile ribotypes circulating in Australian hospitals and communities. J Clin Microbiol. 2017;55:216–25. Provocative study looking at the interaction between the community and the hospital CDI suggesting that the community maybe the source of significant hospital-onset CDI. CrossRef • Fuyura-Kanamori L, Riley TV, Paterson DL, et al. Comparison of Clostridium difficile ribotypes circulating in Australian hospitals and communities. J Clin Microbiol. 2017;55:216–25. Provocative study looking at the interaction between the community and the hospital CDI suggesting that the community maybe the source of significant hospital-onset CDI. CrossRef
18.
Zurück zum Zitat • Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O'Connor L, et al. Diverse sources of C. difficile infection identified on whole genome sequencing. New England J Med. 2013;369:1195–205. Despite some methodologic concerns, this is the largest study demonstrating the likely large contribution of asymptomatic CD carriers to endemic CDI incidence. CrossRef • Eyre DW, Cule ML, Wilson DJ, Griffiths D, Vaughan A, O'Connor L, et al. Diverse sources of C. difficile infection identified on whole genome sequencing. New England J Med. 2013;369:1195–205. Despite some methodologic concerns, this is the largest study demonstrating the likely large contribution of asymptomatic CD carriers to endemic CDI incidence. CrossRef
19.
Zurück zum Zitat Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O'Connor L, et al. Characterization of Clostridium difficile hospital ward-based transmission using extensive epidemiologic data and molecular typing. PLoS Med. 2012;9:e1001172.CrossRefPubMedPubMedCentral Walker AS, Eyre DW, Wyllie DH, Dingle KE, Harding RM, O'Connor L, et al. Characterization of Clostridium difficile hospital ward-based transmission using extensive epidemiologic data and molecular typing. PLoS Med. 2012;9:e1001172.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Noren T, Akerlund T, Back E, Sjoberg L, Persson I, Alriksson I, et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol. 2004;42:3635–43.CrossRefPubMedPubMedCentral Noren T, Akerlund T, Back E, Sjoberg L, Persson I, Alriksson I, et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol. 2004;42:3635–43.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Fisher A, Dembry LLM. Norovirus and Clostridium difficile: squelching the wildfire. Curr Opinion in Infect Dis. 2017;30:440–7.CrossRef Fisher A, Dembry LLM. Norovirus and Clostridium difficile: squelching the wildfire. Curr Opinion in Infect Dis. 2017;30:440–7.CrossRef
22.
Zurück zum Zitat McMullen KM, Zack J, Coopersmith CM, et al. Use of hypochlorite solution to decrease rates of Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol. 2007;28(2007):205–7.CrossRefPubMed McMullen KM, Zack J, Coopersmith CM, et al. Use of hypochlorite solution to decrease rates of Clostridium difficile-associated diarrhea. Infect Control Hosp Epidemiol. 2007;28(2007):205–7.CrossRefPubMed
23.
Zurück zum Zitat Hacek DM, Ogle AM, Fisher A, Robicsek A, Peterson LR. Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. Am J Infect Control. 2010;38:350–3.CrossRefPubMed Hacek DM, Ogle AM, Fisher A, Robicsek A, Peterson LR. Significant impact of terminal room cleaning with bleach on reducing nosocomial Clostridium difficile. Am J Infect Control. 2010;38:350–3.CrossRefPubMed
24.
Zurück zum Zitat Maghdoori S, Moghadas SM. Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings. BMC Infect Dis. 2017;17:384.CrossRefPubMedPubMedCentral Maghdoori S, Moghadas SM. Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings. BMC Infect Dis. 2017;17:384.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT. Epidemiologic model for Clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol. 2011;32:553–61.CrossRefPubMedPubMedCentral Lanzas C, Dubberke ER, Lu Z, Reske KA, Grohn YT. Epidemiologic model for Clostridium difficile transmission in healthcare settings. Infect Control Hosp Epidemiol. 2011;32:553–61.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat • Longtin Y, Paquet-Bolduc B, Gilca R, Garenc C, Fortin E, Longtin J, et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C. difficile infections: a quasi-experimental controlled study. JAMA Intern Med. 2016;176:796–804. Study demonstrating that CDI incidence decreases with aggressive screening and isolation of CD carriers in addition to symptomatic cases. CrossRefPubMed • Longtin Y, Paquet-Bolduc B, Gilca R, Garenc C, Fortin E, Longtin J, et al. Effect of detecting and isolating Clostridium difficile carriers at hospital admission on the incidence of C. difficile infections: a quasi-experimental controlled study. JAMA Intern Med. 2016;176:796–804. Study demonstrating that CDI incidence decreases with aggressive screening and isolation of CD carriers in addition to symptomatic cases. CrossRefPubMed
27.
Zurück zum Zitat WHO guidelines on hand hygiene in health care: first global patient safety challenge clean care is safer care. Geneva: World Health Organization; 2009. WHO guidelines on hand hygiene in health care: first global patient safety challenge clean care is safer care. Geneva: World Health Organization; 2009.
28.
Zurück zum Zitat Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol. 2009;30(10):939–44.CrossRefPubMed Oughton MT, Loo VG, Dendukuri N, Fenn S, Libman MD. Hand hygiene with soap and water is superior to alcohol rub and antiseptic wipes for removal of Clostridium difficile. Infect Control Hosp Epidemiol. 2009;30(10):939–44.CrossRefPubMed
29.
Zurück zum Zitat Jabbar U, Leischner J, Kasper D, Gerber R, Sambol SP, Parada JP, et al. Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol. 2010;31(6):565–70.CrossRefPubMed Jabbar U, Leischner J, Kasper D, Gerber R, Sambol SP, Parada JP, et al. Effectiveness of alcohol-based hand rubs for removal of Clostridium difficile spores from hands. Infect Control Hosp Epidemiol. 2010;31(6):565–70.CrossRefPubMed
30.
Zurück zum Zitat Kundrapu S, Sunkesula V, Jury I, Deshpande A, Donskey CJ. A randomized trial of soap and water hand wash versus alcohol hand rub for removal of Clostridium difficile spores from hands of patients. Infect Control Hosp Epidemiol. 2014;35(2):204–6.CrossRefPubMed Kundrapu S, Sunkesula V, Jury I, Deshpande A, Donskey CJ. A randomized trial of soap and water hand wash versus alcohol hand rub for removal of Clostridium difficile spores from hands of patients. Infect Control Hosp Epidemiol. 2014;35(2):204–6.CrossRefPubMed
31.
Zurück zum Zitat Knight N, Strait T, Anthony N, Lovell R, Norton HJ, Sautter R, et al. Clostridium difficile colitis: a retrospective study of incidence and severity before and after institution of an alcohol-based hand rub policy. Am J Infect Control. 2010;38(7):523–8.CrossRefPubMed Knight N, Strait T, Anthony N, Lovell R, Norton HJ, Sautter R, et al. Clostridium difficile colitis: a retrospective study of incidence and severity before and after institution of an alcohol-based hand rub policy. Am J Infect Control. 2010;38(7):523–8.CrossRefPubMed
32.
Zurück zum Zitat Isaacson D, Haller B, Leslie H, Roemer M, Winston L. Novel handwashes are superior to soap and water in removal of Clostridium difficile spores from the hands. Am J Infect Control. 2015;43(5):530–2.CrossRefPubMed Isaacson D, Haller B, Leslie H, Roemer M, Winston L. Novel handwashes are superior to soap and water in removal of Clostridium difficile spores from the hands. Am J Infect Control. 2015;43(5):530–2.CrossRefPubMed
33.
Zurück zum Zitat Nerandzic MM, Sankar TC, Setlow P, et al. A cumulative spore killing approach: synergistic sporicidal activity of dilute peracetic acid and ethanol at low pH against Clostridium difficile and Bacillus subtilis spores. Open Forum Infect Dis. 2016;3(1):ofv206.CrossRefPubMed Nerandzic MM, Sankar TC, Setlow P, et al. A cumulative spore killing approach: synergistic sporicidal activity of dilute peracetic acid and ethanol at low pH against Clostridium difficile and Bacillus subtilis spores. Open Forum Infect Dis. 2016;3(1):ofv206.CrossRefPubMed
34.
Zurück zum Zitat Zellmer C, Blakney R, Van Hoof S, et al. Impact of sink location on hand hygiene compliance for Clostridium difficile infection. Am J Infect Control. 2015;43(4):387–9.CrossRefPubMed Zellmer C, Blakney R, Van Hoof S, et al. Impact of sink location on hand hygiene compliance for Clostridium difficile infection. Am J Infect Control. 2015;43(4):387–9.CrossRefPubMed
35.
Zurück zum Zitat Kim KH, Fekety R, Batts DH, Brown D, Cudmore M, Silva J, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981;143(1):42–50.CrossRefPubMed Kim KH, Fekety R, Batts DH, Brown D, Cudmore M, Silva J, et al. Isolation of Clostridium difficile from the environment and contacts of patients with antibiotic-associated colitis. J Infect Dis. 1981;143(1):42–50.CrossRefPubMed
36.
Zurück zum Zitat Barbut F. How to eradicate Clostridium difficile from the environment. J Hosp Infect. 2015;89(4):287–95.CrossRefPubMed Barbut F. How to eradicate Clostridium difficile from the environment. J Hosp Infect. 2015;89(4):287–95.CrossRefPubMed
37.
Zurück zum Zitat Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol. 1988;127(6):1289–94.CrossRefPubMed Kaatz GW, Gitlin SD, Schaberg DR, et al. Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol. 1988;127(6):1289–94.CrossRefPubMed
38.
Zurück zum Zitat Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis. 2000;31(4):995–1000.CrossRefPubMed Mayfield JL, Leet T, Miller J, Mundy LM. Environmental control to reduce transmission of Clostridium difficile. Clin Infect Dis. 2000;31(4):995–1000.CrossRefPubMed
39.
Zurück zum Zitat Delclos GL, Gimeno D, Arif AA, Burau KD, Carson A, Lusk C, et al. Occupational risk factors and asthma among health care professionals. Am J Respir Crit Care Med. 2007;175(7):667–75.CrossRefPubMed Delclos GL, Gimeno D, Arif AA, Burau KD, Carson A, Lusk C, et al. Occupational risk factors and asthma among health care professionals. Am J Respir Crit Care Med. 2007;175(7):667–75.CrossRefPubMed
40.
Zurück zum Zitat Sastre J, Madero MF, Fernández-Nieto M, Sastre B, del Pozo V, Potro MGD, et al. Airway response to chlorine inhalation (bleach) among cleaning workers with and without bronchial hyperresponsiveness. Am J Ind Med. 2011;54(4):293–9.CrossRefPubMed Sastre J, Madero MF, Fernández-Nieto M, Sastre B, del Pozo V, Potro MGD, et al. Airway response to chlorine inhalation (bleach) among cleaning workers with and without bronchial hyperresponsiveness. Am J Ind Med. 2011;54(4):293–9.CrossRefPubMed
41.
Zurück zum Zitat • Marra AR, Schweizer ML, Edmond MB. No-touch disinfection methods to decrease multidrug-resistant organism infections: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2018;39(1):20–31. A thoughtful review of newer no-touch disinfection prevention modalities. CrossRefPubMed • Marra AR, Schweizer ML, Edmond MB. No-touch disinfection methods to decrease multidrug-resistant organism infections: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2018;39(1):20–31. A thoughtful review of newer no-touch disinfection prevention modalities. CrossRefPubMed
42.
Zurück zum Zitat • Anderson DJ, Chen LF, Weber DJ, Moehring RW, Lewis SS, Triplett PF, et al. Enhanced terminal room disinfection and acquisition and infection caused by multidrug resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study. Lancet. 2017;389:805–14. Interesting, though largely negative, trial of bleach and UV light compared to standard of care. Results may have been hampered by failure to eradicate CD spores shed by asymptomatic patients in addition to reasons cited in paper and accompanying editorial. CrossRefPubMedPubMedCentral • Anderson DJ, Chen LF, Weber DJ, Moehring RW, Lewis SS, Triplett PF, et al. Enhanced terminal room disinfection and acquisition and infection caused by multidrug resistant organisms and Clostridium difficile (the Benefits of Enhanced Terminal Room Disinfection study): a cluster-randomised, multicentre, crossover study. Lancet. 2017;389:805–14. Interesting, though largely negative, trial of bleach and UV light compared to standard of care. Results may have been hampered by failure to eradicate CD spores shed by asymptomatic patients in addition to reasons cited in paper and accompanying editorial. CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Napolitano NA, Mahapatra T, Tang W. The effectiveness of UV-C radiation for facility-wide environmental disinfection to reduce healthcare-acquired infections. Am J Infect Control. 2015;43:1342–6.CrossRefPubMed Napolitano NA, Mahapatra T, Tang W. The effectiveness of UV-C radiation for facility-wide environmental disinfection to reduce healthcare-acquired infections. Am J Infect Control. 2015;43:1342–6.CrossRefPubMed
44.
Zurück zum Zitat Pegues DA, Han J, Gilmar C, McDonnell B, Gaynes S. Impact of ultraviolet germicidal irradiation for no-touch terminal room disinfection on Clostridium difficile infection incidence among hematology-oncology patients. Infect Control Hosp Epidemiol. 2017;38:39–44.CrossRefPubMed Pegues DA, Han J, Gilmar C, McDonnell B, Gaynes S. Impact of ultraviolet germicidal irradiation for no-touch terminal room disinfection on Clostridium difficile infection incidence among hematology-oncology patients. Infect Control Hosp Epidemiol. 2017;38:39–44.CrossRefPubMed
45.
Zurück zum Zitat Levin J, Riley LS, Parrish C, English D, Ahn S. The effect of portable pulsed xenon ultraviolet light after terminal cleaning on hospital-associated Clostridium difficile infection in a community hospital. Am J Infect Control. 2013;41:746–8.CrossRefPubMed Levin J, Riley LS, Parrish C, English D, Ahn S. The effect of portable pulsed xenon ultraviolet light after terminal cleaning on hospital-associated Clostridium difficile infection in a community hospital. Am J Infect Control. 2013;41:746–8.CrossRefPubMed
46.
Zurück zum Zitat Haas JP, Menz J, Dusza S, Montecalvo MA. Implementation and impact of ultraviolet environmental disinfection in acute care setting. Am J Infect Control. 2014;42:586–90.CrossRefPubMed Haas JP, Menz J, Dusza S, Montecalvo MA. Implementation and impact of ultraviolet environmental disinfection in acute care setting. Am J Infect Control. 2014;42:586–90.CrossRefPubMed
47.
Zurück zum Zitat Miller R, Simmons S, Dale C, Stachowiak J, Stibich M. Utilization and impact of a pulsed-xenon ultraviolet room disinfection system and multidisciplinary care team on Clostridium difficile in a long-term acute care facility. Am J Infect Control. 2015;43:1350–3.CrossRefPubMed Miller R, Simmons S, Dale C, Stachowiak J, Stibich M. Utilization and impact of a pulsed-xenon ultraviolet room disinfection system and multidisciplinary care team on Clostridium difficile in a long-term acute care facility. Am J Infect Control. 2015;43:1350–3.CrossRefPubMed
48.
Zurück zum Zitat Vianna PG, Dale CR Jr, Simmons S, Stibich M, Licitra CM. Impact of pulsed xenon ultraviolet light on hospital-acquired infection rates in a community hospital. Am J Infect Control. 2016;44:299–303.CrossRefPubMed Vianna PG, Dale CR Jr, Simmons S, Stibich M, Licitra CM. Impact of pulsed xenon ultraviolet light on hospital-acquired infection rates in a community hospital. Am J Infect Control. 2016;44:299–303.CrossRefPubMed
49.
Zurück zum Zitat Nagaraja A, Visintainer P, Haas JP, Menz J, Wormser GP, Montecalvo MA. Clostridium difficile infections before and during use of ultraviolet disinfection. Am J Infect Control. 2015;43:940–5.CrossRefPubMed Nagaraja A, Visintainer P, Haas JP, Menz J, Wormser GP, Montecalvo MA. Clostridium difficile infections before and during use of ultraviolet disinfection. Am J Infect Control. 2015;43:940–5.CrossRefPubMed
50.
Zurück zum Zitat Passaretti CL, Otter JA, Reich NG, Myers J, Shepard J, Ross T, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clin Infect Dis. 2013;56(1):27–35.CrossRefPubMed Passaretti CL, Otter JA, Reich NG, Myers J, Shepard J, Ross T, et al. An evaluation of environmental decontamination with hydrogen peroxide vapor for reducing the risk of patient acquisition of multidrug-resistant organisms. Clin Infect Dis. 2013;56(1):27–35.CrossRefPubMed
51.
Zurück zum Zitat Boyce JM, Havill NL, Otter JA, McDonald LC, Adams NMT, Cooper T, et al. Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol. 2008;29:723–9.CrossRefPubMed Boyce JM, Havill NL, Otter JA, McDonald LC, Adams NMT, Cooper T, et al. Impact of hydrogen peroxide vapor room decontamination on Clostridium difficile environmental contamination and transmission in a healthcare setting. Infect Control Hosp Epidemiol. 2008;29:723–9.CrossRefPubMed
52.
Zurück zum Zitat Horn K, Otter JA. Hydrogen peroxide vapor room disinfection and hand hygiene improvements reduce Clostridium difficile infection, methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and extended-spectrum β-lactamase. Am J Infect Control. 2015;43:1354–6.CrossRefPubMed Horn K, Otter JA. Hydrogen peroxide vapor room disinfection and hand hygiene improvements reduce Clostridium difficile infection, methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and extended-spectrum β-lactamase. Am J Infect Control. 2015;43:1354–6.CrossRefPubMed
53.
Zurück zum Zitat Manian FA, Griesnauer S, Bryant A. Implementation of hospital-wide enhanced terminal cleaning of targeted patient rooms and its impact on endemic Clostridium difficile infection rates. Am J Infect Control. 2013;41:537–41.CrossRefPubMed Manian FA, Griesnauer S, Bryant A. Implementation of hospital-wide enhanced terminal cleaning of targeted patient rooms and its impact on endemic Clostridium difficile infection rates. Am J Infect Control. 2013;41:537–41.CrossRefPubMed
54.
Zurück zum Zitat McCord J, Prewitt M, Dyakova E, Mookerjee S, Otter JA. Reduction in Clostridium difficile infection associated with the introduction of hydrogen peroxide vapour automated room disinfection. J Hosp Infect. 2016;94:185–7.CrossRefPubMed McCord J, Prewitt M, Dyakova E, Mookerjee S, Otter JA. Reduction in Clostridium difficile infection associated with the introduction of hydrogen peroxide vapour automated room disinfection. J Hosp Infect. 2016;94:185–7.CrossRefPubMed
55.
Zurück zum Zitat Gateau C, Couturier J, Coia J, Barbut F. How to: diagnose infection caused by Clostridium difficile. Clin Microbiol Infect. 2018; in press. Gateau C, Couturier J, Coia J, Barbut F. How to: diagnose infection caused by Clostridium difficile. Clin Microbiol Infect. 2018; in press.
56.
Zurück zum Zitat Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl 4):S63–81.CrossRefPubMed Crobach MJT, Planche T, Eckert C, Barbut F, Terveer EM, Dekkers OM, et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2016;22(Suppl 4):S63–81.CrossRefPubMed
57.
Zurück zum Zitat Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald L, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and in the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRefPubMed Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald L, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and in the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.CrossRefPubMed
58.
Zurück zum Zitat Planche T, Wilcox MH. Diagnostic pitfalls in Clostridium difficile infection. Infect Dis Clin N Am. 2015;29(1):63–82.CrossRef Planche T, Wilcox MH. Diagnostic pitfalls in Clostridium difficile infection. Infect Dis Clin N Am. 2015;29(1):63–82.CrossRef
59.
Zurück zum Zitat Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis. 2013;13(11):936–45.CrossRefPubMedPubMedCentral Planche TD, Davies KA, Coen PG, Finney JM, Monahan IM, Morris KA, et al. Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C. difficile infection. Lancet Infect Dis. 2013;13(11):936–45.CrossRefPubMedPubMedCentral
60.
Zurück zum Zitat Bartlett JG. Clostridium difficile infection. Infect Dis Clin N Am. 2017;31(3):489–95.CrossRef Bartlett JG. Clostridium difficile infection. Infect Dis Clin N Am. 2017;31(3):489–95.CrossRef
61.
Zurück zum Zitat Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol. 2013;51(3):869–73.CrossRefPubMedPubMedCentral Humphries RM, Uslan DZ, Rubin Z. Performance of Clostridium difficile toxin enzyme immunoassay and nucleic acid amplification tests stratified by patient disease severity. J Clin Microbiol. 2013;51(3):869–73.CrossRefPubMedPubMedCentral
62.
Zurück zum Zitat Carman RJ, Wickham KN, Chen L, Lawrence AM, Boone JH, Wilkins TD, et al. Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes. J Clin Microbiol. 2012;50(4):1425–6.CrossRefPubMedPubMedCentral Carman RJ, Wickham KN, Chen L, Lawrence AM, Boone JH, Wilkins TD, et al. Glutamate dehydrogenase is highly conserved among Clostridium difficile ribotypes. J Clin Microbiol. 2012;50(4):1425–6.CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults. JAMA. 2015;313(4):398–408.CrossRefPubMed Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults. JAMA. 2015;313(4):398–408.CrossRefPubMed
64.
Zurück zum Zitat • Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175(11):1792. Important study used as justification to move away from nucleic acid testing for CDI. CrossRefPubMedPubMedCentral • Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med. 2015;175(11):1792. Important study used as justification to move away from nucleic acid testing for CDI. CrossRefPubMedPubMedCentral
65.
Zurück zum Zitat Rees WD, Steiner TS. Adaptive immune response to Clostridium difficile infection: a perspective for prevention and therapy. Eur J Immunol. 2018;00:1–9. Rees WD, Steiner TS. Adaptive immune response to Clostridium difficile infection: a perspective for prevention and therapy. Eur J Immunol. 2018;00:1–9.
66.
Zurück zum Zitat Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305–17.CrossRefPubMed Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305–17.CrossRefPubMed
67.
Zurück zum Zitat De Bruyne G, Saleh J, Workman D, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized phase 2 trial. Vaccine. 2016;34:2170–8.CrossRef De Bruyne G, Saleh J, Workman D, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: a randomized phase 2 trial. Vaccine. 2016;34:2170–8.CrossRef
69.
Zurück zum Zitat Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–7.CrossRefPubMed Kyne L, Warny M, Qamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390–7.CrossRefPubMed
70.
Zurück zum Zitat Zhang K, Zhao S, Wang Y, Zhu X, Shen H, Chen Y, et al. The non-toxigenic Clostridium difficile strain CD37 protects mice against infection with a B1/NAP1/027 type of C. difficile strain. Anaerobe. 2015;36:49–52.CrossRefPubMedPubMedCentral Zhang K, Zhao S, Wang Y, Zhu X, Shen H, Chen Y, et al. The non-toxigenic Clostridium difficile strain CD37 protects mice against infection with a B1/NAP1/027 type of C. difficile strain. Anaerobe. 2015;36:49–52.CrossRefPubMedPubMedCentral
71.
Zurück zum Zitat Nagaro KJ, Philllips ST, Cheknis AK, et al. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic B1/NAP1/027 C. difficile. Animicrob Agents Chemother. 2013;57:5266–70.CrossRef Nagaro KJ, Philllips ST, Cheknis AK, et al. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic B1/NAP1/027 C. difficile. Animicrob Agents Chemother. 2013;57:5266–70.CrossRef
72.
Zurück zum Zitat Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonization with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents. 2009;33(suppl 1):s46–50.CrossRefPubMed Merrigan MM, Sambol SP, Johnson S, Gerding DN. New approach to the management of Clostridium difficile infection: colonization with non-toxigenic C. difficile during daily ampicillin or ceftriaxone administration. Int J Antimicrob Agents. 2009;33(suppl 1):s46–50.CrossRefPubMed
73.
Zurück zum Zitat Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. Evaluation of an oral suspension of VP20621, spores of a nontoxigenic Clostridium difficile strain M3, in healthy subjects. Animicrob Agents Chemother. 2012;56:5224–9.CrossRef Villano SA, Seiberling M, Tatarowicz W, Monnot-Chase E, Gerding DN. Evaluation of an oral suspension of VP20621, spores of a nontoxigenic Clostridium difficile strain M3, in healthy subjects. Animicrob Agents Chemother. 2012;56:5224–9.CrossRef
74.
Zurück zum Zitat Goldenberg JZ, Yap C, Lytvyn L, Lo CKF, Beardsley J, Mertz D, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Systemat Rev. 2017;12:CD006095. Goldenberg JZ, Yap C, Lytvyn L, Lo CKF, Beardsley J, Mertz D, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Systemat Rev. 2017;12:CD006095.
75.
Zurück zum Zitat Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;60(suppl_2):S122–8.CrossRefPubMed Evans CT, Johnson S. Prevention of Clostridium difficile infection with probiotics. Clin Infect Dis. 2015;60(suppl_2):S122–8.CrossRefPubMed
76.
Zurück zum Zitat Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214:173–81.CrossRefPubMed Khanna S, Pardi DS, Kelly CR, Kraft CS, Dhere T, Henn MR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis. 2016;214:173–81.CrossRefPubMed
77.
Zurück zum Zitat Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology. 2017;152:799–811.e7.CrossRefPubMed Ott SJ, Waetzig GH, Rehman A, Moltzau-Anderson J, Bharti R, Grasis JA, et al. Efficacy of sterile fecal filtrate transfer for treating patients with Clostridium difficile infection. Gastroenterology. 2017;152:799–811.e7.CrossRefPubMed
78.
Zurück zum Zitat Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepiński P, Douce GR, et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2016;60:968–81.CrossRefPubMedPubMedCentral Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepiński P, Douce GR, et al. Bacteriophage combinations significantly reduce Clostridium difficile growth in vitro and proliferation in vivo. Antimicrob Agents Chemother. 2016;60:968–81.CrossRefPubMedPubMedCentral
Metadaten
Titel
Primary Prevention of Clostridium difficile-Associated Diarrhea: Current Controversies and Future Tools
verfasst von
Zachary A. Rubin
Elise M. Martin
Paul Allyn
Publikationsdatum
01.09.2018
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 9/2018
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-018-0639-4

Weitere Artikel der Ausgabe 9/2018

Current Infectious Disease Reports 9/2018 Zur Ausgabe

Tropical, Travel, and Emerging Infections (L Chen and A Boggild, Section Editors)

Travel and the Spread of Drug-Resistant Bacteria

Tropical, Travel and Emerging Infection (L Chen and A Boggild, Section Editors)

Evolving Epidemiology of Japanese Encephalitis: Implications for Vaccination

Healthcare Associated Infections (G Bearman and D Morgan, Section Editors)

The Current State of Antimicrobial Stewardship: Challenges, Successes, and Future Directions

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.